XML 39 R29.htm IDEA: XBRL DOCUMENT
v3.21.2

GOODWILL AND INTANGIBLE ASSETS (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of Goodwill | The following table summarizes the changes in the carrying amount of goodwill:
(in millions) |  | Amount |
Balance at December 31, 2020 |  | $ | 8,108 |  |
Goodwill resulting from the acquisition of MYR |  | 226 |  |
Measurement period adjustments |  | (2) |  |
Balance at September 30, 2021 |  | $ | 8,332 |  |
Schedule of Finite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | September 30, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (5,477) |  |  | $ | — |  |  | $ | 5,243 |  |  | $ | 10,720 |  |  | $ | (4,952) |  |  | $ | — |  |  | $ | 5,768 |
Intangible asset - axicabtagene ciloleucel(1) |  | 7,110 |  |  | (1,400) |  |  | — |  |  | 5,710 |  |  | 6,200 |  |  | (1,105) |  |  | — |  |  | 5,095 |
Intangible asset - Trodelvy(2) |  | 5,630 |  |  | (390) |  |  | — |  |  | 5,240 |  |  | 4,600 |  |  | (63) |  |  | — |  |  | 4,537 |
Intangible asset - Hepcludex |  | 845 |  |  | (50) |  |  | — |  |  | 795 |  |  | — |  |  | — |  |  | — |  |  | — |
Other |  | 1,410 |  |  | (619) |  |  | 1 |  |  | 792 |  |  | 1,377 |  |  | (540) |  |  | (1) |  |  | 836 |
Total finite-lived assets |  | 25,715 |  |  | (7,936) |  |  | 1 |  |  | 17,780 |  |  | 22,897 |  |  | (6,660) |  |  | (1) |  |  | 16,236 |
Indefinite-lived assets - IPR&D(1)(2)(3)(4) |  | 16,120 |  |  | — |  |  | — |  |  | 16,120 |  |  | 16,890 |  |  | — |  |  | — |  |  | 16,890 |
Total intangible assets |  | $ | 41,835 |  |  | $ | (7,936) |  |  | $ | 1 |  |  | $ | 33,900 |  |  | $ | 39,787 |  |  | $ | (6,660) |  |  | $ | (1) |  |  | $ | 33,126 |
_______________________________ (1) Gross carrying amount as of September 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma. (2) Gross carrying amount as of September 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D. (3) Gross carrying amount as of September 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information. (4) In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million will be reclassified to finite-lived assets in the fourth quarter of 2021.
Schedule of Indefinite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | September 30, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (5,477) |  |  | $ | — |  |  | $ | 5,243 |  |  | $ | 10,720 |  |  | $ | (4,952) |  |  | $ | — |  |  | $ | 5,768 |
Intangible asset - axicabtagene ciloleucel(1) |  | 7,110 |  |  | (1,400) |  |  | — |  |  | 5,710 |  |  | 6,200 |  |  | (1,105) |  |  | — |  |  | 5,095 |
Intangible asset - Trodelvy(2) |  | 5,630 |  |  | (390) |  |  | — |  |  | 5,240 |  |  | 4,600 |  |  | (63) |  |  | — |  |  | 4,537 |
Intangible asset - Hepcludex |  | 845 |  |  | (50) |  |  | — |  |  | 795 |  |  | — |  |  | — |  |  | — |  |  | — |
Other |  | 1,410 |  |  | (619) |  |  | 1 |  |  | 792 |  |  | 1,377 |  |  | (540) |  |  | (1) |  |  | 836 |
Total finite-lived assets |  | 25,715 |  |  | (7,936) |  |  | 1 |  |  | 17,780 |  |  | 22,897 |  |  | (6,660) |  |  | (1) |  |  | 16,236 |
Indefinite-lived assets - IPR&D(1)(2)(3)(4) |  | 16,120 |  |  | — |  |  | — |  |  | 16,120 |  |  | 16,890 |  |  | — |  |  | — |  |  | 16,890 |
Total intangible assets |  | $ | 41,835 |  |  | $ | (7,936) |  |  | $ | 1 |  |  | $ | 33,900 |  |  | $ | 39,787 |  |  | $ | (6,660) |  |  | $ | (1) |  |  | $ | 33,126 |
_______________________________ (1) Gross carrying amount as of September 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma. (2) Gross carrying amount as of September 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D. (3) Gross carrying amount as of September 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information. (4) In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million will be reclassified to finite-lived assets in the fourth quarter of 2021.
Schedule of Estimated Future Amortization Expense | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2021:
(in millions) |  | Amount
2021 (remaining three months) |  | $ | 441 |
2022 |  | 1,764 |
2023 |  | 1,764 |
2024 |  | 1,764 |
2025 |  | 1,759 |
Thereafter |  | 10,288 |
Total |  | $ | 17,780 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration